表 1.

EGFR突变阴性与突变阳性NSCLC的脑转移临床特点

Clinical features of brain metastases between EGFR mutation negative and EGFR mutation positive NSCLC

Index	Incidence at diagnosis	3-year cumulative incidence	Onset time (median)	Common site	Number (median)	Size (median)	Incidence of CNS symptoms	CNS ORR of drug	CNS PFS (median)
EGFR: epidermal growth factor receptor; CNS: central nervous system; ORR: overall response rate; PFS: progression-free survival; NR: not reached; NSCLC: non-small cell lung cancer.
EGFR mutation negative	24.6%-25.1%	28.2%-39.2%	7 mon-14 mon	Frontal lobe and parietal lobe	2-3	5.6 mm-11 mm	18.5%-57.5%	15.0%-53.8%	2.3 mon-24.3 mon
EGFR mutation positive	26.0%-30.6%	39.2%-46.2%	9.6 mon-19 mon	Frontal lobe and parietal lobe	4-5	4.8 mm-7.1 mm	7.7%-37.8%	43.0%-70.0%	10 mon-NR